Many recent clinical studies of NSCLC in perioperative settings use one of the PD-1 inhibitors (nivolumab, pembrolizumab, cemiplimab, sintilimab, and toripalimab) or PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab). This evidence concerns the gene CD274 and non-small cell lung carcinoma.